Associated Papers
Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.
Tahaney WM et al.
Breast Cancer Research and Treatment, 2026
41493644 (PubMed )
Supplement: 10549_2025_7865_MOESM12_ESM.xlsx › Table_S2
Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.
Chen SH et al.
Cancer Medicine, 2024
38895905 (PubMed )
Supplement: CAM4-13-e7384-s003.xlsx › Sheet1
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers.
Payton M et al.
Nature Cancer, 2024
38151625 (PubMed )
Supplement: 43018_2023_699_MOESM2_ESM.xls › Suppl_Table_S3_PRISM
Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Wang XY et al.
Theranostics, 2022
34987644 (PubMed )
Supplement: thnov12p0260s1.pdf
Association of MicroRNA-21 with p53 at Mutant Sites R175H and R248Q, Clinicopathological Features, and Prognosis of NSCLC.
Zhou Y et al.
Molecular Therapy Oncolytics, 2020
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
32732999 (PubMed )
Supplement: 41467_2020_17659_MOESM3_ESM.xls › TableS1
Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.
Brieghel C et al.
Haematologica, 2019
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential.
Wong TN et al.
Nature Communications, 2018
29386642 (PubMed )
Supplement: 41467_2018_2858_MOESM8_ESM.xlsx › TAML-TMDS
Proteogenomics connects somatic mutations to signalling in breast cancer.
Mertins P et al.
Nature, 2016
27251275 (PubMed )
Supplement: NIHMS778057-supplement-supp_table1.xlsx › CPTAC_Sample_Annotation
Select a paper to view details